ZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Zenas BioPharma, Inc. for violations of federal securities laws related to misleading statements made during its IPO [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated by the Schall Law Firm, which specializes in shareholder rights litigation [1][5]. - Investors who purchased Zenas securities during its IPO on September 13, 2024, are encouraged to contact the firm for participation in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Zenas BioPharma - The complaint alleges that Zenas made false and misleading statements regarding its financial status, specifically overstating the runway of funded operations based on existing cash and expected IPO proceeds [4]. - The misleading public statements were made throughout the IPO period, leading to investor damages once the truth was revealed [4].